HCAR2 and type 2 diabetes mellitus: In combination, in vivo application of 1,3-BDO resulted in reduced FBG, insulin resistance level and tissue injury through HCAR2 in T2D mice, strongly supporting the potential therapeutic value of 3HB in T2D.